Virax Biolabs
VRAX
4 hedge funds and large institutions have $202K invested in Virax Biolabs in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
1,572% more capital invested
Capital invested by funds: $12.1K → $202K (+$190K)
0.81% more ownership
Funds ownership: 0.03% → 0.85% (+0.81%)
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$216K |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
+$9.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$7.41K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.59K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$2.07K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $193K | +$216K | +35,152 | New |
|
|
JF
2
Jump Financial
Chicago,
Illinois
| $8.96K | +$9.99K | +1,629 | New |
|
|
FFA
3
Farther Finance Advisors
San Francisco,
California
| $4 | – | – | – |
|
4
Osaic Holdings
Scottsdale,
Arizona
| $4 | – | – | – |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| – | -$7.41K | -857 | Closed |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$2.59K | -300 | Closed |
|
|
7
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$2.07K | -240 | Closed |
|
|
8
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$3 | – | – |
|
VRAX Hedge Fund Activity: Q1 2026 in Review
4 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q1 2026, worth a combined $202K — up 1,572% from $12.1K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VRAX and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $216K. The largest seller was XTX Topco, exiting entirely with an estimated $7.41K sold.
- 4 institutional investors held Virax Biolabs (VRAX) as of Q1 2026, down from 5 in Q4 2025.
- Funds reported $202K of Virax Biolabs stock for Q1 2026, up 1,572% quarter-over-quarter.
- 2 funds opened new Virax Biolabs positions in Q1 2026 and 3 closed out, a net change of -1 holder.
- The largest Virax Biolabs buyer in Q1 2026 was Armistice Capital, an estimated $216K added.
- The largest Virax Biolabs seller in Q1 2026 was XTX Topco, an estimated $7.41K sold.
Based on aggregated 13F filings for Q1 2026.